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Mei He,§a Jennifer Crow,a Marc Roth,a Yong Zeng*b
and Andrew K. Godwin*ac
Developing blood-based tests is appealing for non-invasive disease diagnosis, especially when biopsy is
difficult, costly, and sometimes not even an option. Tumor-derived exosomes have attracted increasing
interest in non-invasive cancer diagnosis and monitoring of treatment response. However, the biology and
clinical value of exosomes remains largely unknown due in part to current technical challenges in rapid
isolation, molecular classification and comprehensive analysis of exosomes. Here we developed a new
microfluidic approach to streamline and expedite the exosome analysis pipeline by integrating specific
immunoisolation and targeted protein analysis of circulating exosomes. Compared to the conventional
methods, our approach enables selective subpopulation isolation and quantitative detection of surface and
intravesicular biomarkers directly from a minimally invasive amount of plasma samples (30 μL) within
~100 min with markedly improved detection sensitivity. Using this device, we demonstrated phenotyping
of exosome subpopulations by targeting a panel of common exosomal and tumor-specific markers and
multiparameter analyses of intravesicular biomarkers in the selected subpopulation. We were able to assess
the total expression and phosphorylation levels of IGF-1R in non-small-cell lung cancer patients by probing
plasma exosomes as a non-invasive alternative to conventional tissue biopsy. We foresee that the
microfluidic exosome analysis platform will form the basis for critically needed infrastructures for advancing
the biology and clinical utilization of exosomes.Introduction
Developing non-invasive blood-based tests is extremely
appealing for presymptomatic screening and early detection
of cancers where obtaining tissue biopsy is highly invasive
and costly. This is particularly true for many primary tumors
and most metastatic diseases. Probing circulating exosomes
becomes an emerging paradigm for cancer detection andmonitoring response to treatment. Most eukaryotic cells
release exosomes that are membrane vesicles derived from
the endolysosomal pathway with a size range of ~30–150 nm.1
Exosomes play important biological roles via transfer of
cargo consisting of proteins, RNAs,2,3 and mitochondrial
DNA.4 They have been found to be abundant in plasma and
malignant effusions derived from cancer patients.5–7 The
constitutive release of exosomes with selectively enriched
biomolecules presents distinctive opportunities for cancer
diagnosis.8,9 However, exosome research has been severely
constrained by the technical difficulties in isolation and
molecular analysis of such nano-scale and molecularly
diverse vesicles.1 Standard exosome isolation protocols
heavily rely on multiple-step ultracentrifugation which is
tedious, time consuming (>10 h) and inefficient.10 Moreover,
ultracentrifugation co-purifies various vesicle subtypes
secreted via different intracellular mechanisms, which may
mask disease-related biosignatures.11 Size-exclusion methods
normally do not concentrate exosomes and are prone to
pressure-caused damage of vesicles12 and contaminations.13
Standard techniques widely used for exosome analysis, such
as western blot, ELISA and mass spectrometry, require
lengthy processes and large sample volumes, thus limiting, 2014, 14, 3773–3780 | 3773
Fig. 1 Integrated microfluidic exosome analysis directly from human
plasma. (A) Image of the prototype PDMS chip containing a cascading
microchannel network for multi-stage exosome analysis. (B) Streamlined
workflow for on-chip immunomagnetic isolation, chemical lysis, and
intravesicular protein analysis of circulating exosomes. #1–4 indicates the
inlet for exosome capture beads, washing/lysis buffer, protein capture
beads, and ELISA reagents, respectively. (C, D) Typical TEM images of
exosomes from NSCLC (C) and ovarian cancer plasma (D) isolated by
the microfluidic immunomagnetic method. The magnetic beads were
conjugated with anti-EpCAM and anti-CA125 antibodies for NSCLC
and ovarian cancer, respectively. (E, F) TEM images showing large
aggregates (E) and other membranous particles (F) observed in the
ultracentrifugation-purified vesicles, as indicated by the white arrows.
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View Article Onlineclinical investigation. To date, there are no well-defined
protocols for isolation and molecular characterization of
exosomes.1,13
Microfluidics has shown unique advantages for bioassays,
such as high throughput,14,15 single-molecule and single-cell
sensitivity,16–19 functional integration18,20–22 and automa-
tion.23,24 Although recent advancements in microfluidic tech-
nology have made an enormous impact on biological and
medical sciences, much less efforts have been invested
in applying microfluidic technology to accelerate exosome
research. Recently, two flow-through microchips with surface-
immobilized antibodies have been reported for solid-phase
immunocapture and surface characterization of exosomes.20,25
A microfiltration system was developed for size isolation of
microvesicles by integrating a porous polymer membrane.26
On-chip surface phenotyping of microvesicles has also been
demonstrated by using miniaturized nuclear magnetic reso-
nance27 and nano-plasmonic sensors.28 While these systems
markedly improved the performance for exosome isolation and
detection, they still rely on conventional analysis techniques
to probe intravesicular constituents, limiting the ability for
comprehensive characterization of exosomes.
Here we report for the first time an integrated microfluidic
approach that enables on-chip immunoisolation and in situ
protein analysis of exosomes directly from patient plasma.
Specifically, a cascading microfluidic circuit was designed
to streamline and expedite the pipeline for proteomic
characterization of circulating exosomes, including exosome
isolation and enrichment, on-line chemical lysis, protein
immunoprecipitation, and sandwich immunoassays assisted
by chemifluorescence detection. Compared to the conven-
tional methods, our technology remarkably increases the sen-
sitivity while reducing the assay time and sample requirement
by two orders of magnitude. The integrative exosome analysis
and the ability to probe intravesicular contents distinguish
our platform from the existing microfluidic devices.
We applied the technology to analyze clinical plasma
specimens, mainly from non-small-cell lung cancer (NSCLC)
patients. Lung cancer is the leading cause of cancer-related
deaths worldwide29 and NSCLC accounts for approximately
85% of lung cancer cases with an overall 5 year survival rate
of only 15% (stage IIIA).30 Since the majority of NSCLC
patients present with unresectable advanced disease,
obtaining adequate tissue for diagnosis can be challenging.
Furthermore, it is extremely difficult to obtain tissue biopsies
prior to each therapy, which substantially limits the histo-
logic and molecular information.31 Herein we demonstrated
selective isolation of exosomes from NSCLC plasma and
quantitative analysis of total expression and phosphorylation
levels of type 1 insulin growth factor receptor (IGF-1R), a
promising biomarker and therapeutic target for NSCLC.32 In
contrast, current clinical assessment of IGF-1R expression
primarily relies on immunohistochemical (IHC) tests of
tumor tissues which are highly invasive.33 Because of the
advantages of high sensitivity, fast speed, and small sample
demand, the microfluidic exosome analysis technology3774 | Lab Chip, 2014, 14, 3773–3780developed here might open a new avenue for cancer diagno-
sis in a non-invasive manner, i.e., liquid biopsy.
Results and discussion
Integrated microfluidic exosome analysis platform
Our microfluidic technology uses a magnetic bead-based
strategy to integrate and streamline the multi-step analysis
of exosomes directly from human plasma (Fig. 1A).
Compared to the surface-based exosome microchips,20,25 the
immunomagnetic method allows for enrichment of captured
exosomes and convenient sample preparation for transmis-
sion electron microscopy (TEM) characterization in addition
to higher capture efficiency and analysis sensitivity due to
the larger surface area.34 The PDMS chip that we have
devised uses a cascading microchannel circuit to sequentially
conduct exosome isolation and enrichment (1st-stage
capture), chemical lysis and immunoprecipitation of intra-
vesicular targets (2nd-stage capture), and chemifluorescence-
assisted sandwich immunoassay (Fig. 1A and ESI,‡ Table S2).
Briefly, the plasma sample pre-mixed with antibody-labeled
magnetic beads was introduced through inlet #1 into the first
chamber where the magnetic beads were retained and
washed with PBS buffer (Fig. 1B(1), Movie S1‡). A lysis buffer
was then introduced through inlet #2 to fill the chamber and
then the flow was stopped to incubate the captured exo-
somes. The lysate was flowed into a serpentine channel and
the antibody-labeled magnetic beads were injected from two
side channels to capture the released intravesicular proteins
(Fig. 1B(2)). The protein capture beads were magneticallyThis journal is © The Royal Society of Chemistry 2014
Fig. 2 Microfluidic immunomagnetic capture of circulating exosomes.
(A) Plot of the amount of beads captured in the chamber represented
by the aggregate area fraction as a function of total infusion volume
(circle) and flow rate (square). The error bars are standard deviations
(n = 3). Inset: a bright-field image of the magnetic capture of beads in
the 1st capture chamber. The scale bar is 100 μm. (B) Representative
TEM images showing enriched exosomes on the surface of antibody-
conjugated beads from NSCLC and ovarian cancer (OVCA) samples,
while significantly fewer vesicles from healthy plasma and almost no
vesicles on the negative control beads without specific antibodies were
observed. (C) Representative size histograms of on-chip isolated
exosomes from NSCLC (EpCAM+, n = 130) and OVCA (CA125+,
n = 130) compared to that of ultracentrifugation-purified NSCLC
vesicles measured by NTA using NanoSight (insets). Sizes were
obtained by averaging five measurements. Red dot plots are log-normal
fitting (R2 > 0.98). Scale bars: 100 nm.
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View Article Onlineretained in the 2nd chamber where detection antibodies and
chemifluorescence reagents were sequentially introduced for
sandwich immunodetection of protein markers of interest
(Fig. 1B(3)). The buffers for binding and washing have been
optimized to minimize bead aggregation and non-specific
adsorption while maintaining the integrity of captured
exosomes (see the ESI‡). The on-chip assay can be completed
in less than 1.5 h and uses plasma sample volumes as low as
30 μL.
Fig. 1C & D show the representative TEM images of
on-chip isolated exosomes from NSCLC and ovarian cancer
(OVCA), respectively. We observed a typical round, homoge-
neous morphology of exosomes which were carefully pre-
pared by embedding and sectioning for TEM imaging. The
cup shape of exosomes was often observed by electron
microscopy, which likely resulted from drying-caused
collapse of vesicles.11 A major size distribution of 40–150 nm
was determined, which is consistent with the reported size
range.35 For comparison, we purified the exosomes by
the gold standard method, ultracentrifugation, and often
observed a heterogeneous population of vesicles containing
relatively large aggregates and other membranous particles
(Fig. 1E & F). It is worth mentioning that at the early stage of
technical development, we also explored the immunocapture
of ultracentrifugation-purified exosomes for parallel evalua-
tion of the one-step microfluidic isolation. However, the
capture efficiency was found to be considerably low and
variable, which may be attributed to the fact that the recovery
rate of ultracentrifugation is low (5–25%)36 and further
reduced by the additional immunocapture steps. In addition,
we observed much more irregular vesicles bound to the beads
by TEM, which appear to be collapsed or damaged (Fig. S1‡).On-chip immunomagnetic isolation of circulating exosomes
We first investigated the magnetic capture of beads as it
dictates the overall performance of exosome isolation and
analysis. The beads suspended in a buffer solution were
retained by a magnet placed underneath the capture cham-
ber (Fig. 2A, inset), forming an aggregate (Fig. S2‡) induced
by the dipolar interactions between the beads. It was reported
that the amount of magnetically captured beads in a micro-
channel can be represented by the size of the bead aggregate,
which increases linearly with time at a constant flow rate.37
We adopted this approach to conveniently assess the bead
capture as a function of flow conditions (Fig. 2A). It was
found that the aggregate size was linearly dependent on the
total sample infusion volume regardless of the flow rates
applied to reach certain infusion volumes (1–10 μL min−1,
Fig. 2A). The independence on flow rate indicates the high
bead capture efficiency and capacity of our system, which
ensures quantitative measurement of exosomes over a wide
range of flow conditions and sample volumes. We chose low
flow rates for affinity capture of exosomes and protein targets
released by chemical lysis (2 μL min−1 and 1 μL min−1,
respectively), at which the bead recovery efficiency wasThis journal is © The Royal Society of Chemistry 2014determined to be >99.9% by counting the residual beads in
the eluent.
To verify the capture specificity and generalizability of our
method, we compared the on-chip purification of exosomes
from NSCLC, OVCA, and healthy plasma using beads labeled
with monoclonal antibodies specific for epithelial cell
adhesion molecules (EpCAM), IGF-1R α units (α-IGF-1R) or
CA125. TEM examination shows that the antibody beads were
densely coated with vesicles from the patient sample, while
significantly fewer vesicles from healthy plasma and almost
no vesicles on the negative control beads without specific
antibodies were observed. These results confirm the specific
binding of exosomes and effective washing to minimize non-
specific binding. Moreover, we examined by TEM numerous
exosomes isolated by targeting various surface markers.
The majority of these exosomes remained intact, in contrast
to the much more damaged vesicles observed for the
immunocapture of vesicles pre-purified by ultracentrifugation
(Fig. S1‡). This indicates the advantage of the direct one-step
microfluidic immunoisolation to preserve vesicle integrity
over the conventional ultracentrifugation-based protocols.10,11,20
The on-chip capture performance was further character-
ized by the size distribution of individual exosome subpopu-
lations isolated by targeting both tumor-associated markers
(EpCAM, α-IGF-1R, and CA125) and common exosomalLab Chip, 2014, 14, 3773–3780 | 3775
Fig. 3 Microfluidic isolation and surface phenotyping of circulating
exosomes in cancer. (A) The scattered dot plot of the abundance
of bead-bound exosomes from NSCLC, OVCA and healthy plasma
obtained by TEM (n = 25). A panel of surface markers (EpCAM, α-IGF-1R,
CA125, CD9, CD81 and CD63) were used for exosome isolation. The
dashed line indicates the highest exosome counts observed for healthy
controls. (B) NTA analysis of the size distribution and abundance of vesi-
cles purified from NSCLC and healthy controls by ultracentrifugation.
The error bars are the standard deviations. The dashed lines are
2
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View Article Onlinemarkers (CD9, CD81, and CD63).38 Size is the most accept-
able criterion for exosome identification39 and differentiation
from other extracellular vesicle types.40 The current consen-
sus is that exosomes originated from multivesicular endo-
some fusion are typically smaller than 150 nm while the
majority of microvesicles derived from plasma membranes
are relatively larger (150–2000 nm).1 Compared to nanoparti-
cle tracking analysis (NTA) using NanoSight which requires
~1 mL of concentrated vesicles (~109 mL−1) for accurate size
determination, TEM provides a robust means of sizing and
counting exosomes in small volumes collected from micro-
fluidic isolation without significant dilution (~30 μL). Most
immunocaptured exosomes were found to be smaller than
150 nm with a notably smaller size range (e.g., 97% of
EpCAM+ and CA125+ vesicles <150 nm) than those obtained
by ultracentrifugation (72.1%) (Fig. 2C and S3‡). Current
“gold standard” approaches based on ultracentrifugation
yield a mixed population of various extracellular vesicle types
with a wide size distribution.41 Indeed, our NTA analysis of
ultracentrifugation-purified vesicles yielded a broader size
variation and no distinct profiles between healthy and NSCLC
cases (Fig. 2C and S4‡). These findings suggest that our
microfluidic immunocapture method provides a more spe-
cific means of purifying exosomes than ultracentrifugation.log-normal fitting (R > 0.98). (C) Bradford assay of total proteins in
ultracentrifugation-purified exosomes from NSCLC patients (stage II)
and healthy subjects (p = 0.0007). (D) Representative IFH images of the
matched tumor tissue from NSCLC patient #1 in (A) showing high
expression of the biomarkers except for CD63.Profiling of exosome subpopulations defined by surface
protein phenotypes
The surface protein composition of exosomes plays an impor-
tant role in exosome-mediated effects42 and may provide
tumor fingerprints.27,28 To demonstrate the ability to detect
exosomal expression patterns associated with cancer, we
conducted relative quantification of five exosome subpopula-
tions defined by individual surface markers using TEM.
Fig. 3A shows the results for two of the NSCLC samples that
we have tested. Distinct subpopulation landscapes were
observed as compared to the healthy controls with a 3- to
5-fold increase in abundance for the surface markers except
CD63. We further demonstrated the adaptability of our
method to other cancers by testing OVCA with the tumor
markers (EpCAM and CA125) and exosomal markers (CD9,
CD81, and CD63). The OVCA samples also provided a positive
control for the NSCLC studies, as CD63 was found to be
highly expressed in OVCA exosomes.43 As expected, high
CD63 expression was observed, which validates our method
and supports the observation of low CD63 expression in
NSCLC cases. The abilities to discriminate disease from
healthy subjects and to detect differential expression of markers
(e.g., CD63) in cancers indicate the high immunocapture
specificity of our microfluidic method.
To verify the microfluidic results, we performed parallel
analyses of the NSCLC samples using standard ultracentrifu-
gation and analytical methods. Exosome abundance in the
patient plasma measured by NTA showed a ~4-fold increase
on average compared to the healthy controls ( p = 0.0001,
Fig. 3B and S5‡), in line with the total protein levels3776 | Lab Chip, 2014, 14, 3773–3780determined by the Bradford assay (a 3.9-fold increase on
average, p = 0.0007, Fig. 3C). Western blotting analysis
showed increased exosomal expression of CD9, CD81, and
IGF-1R markers but indiscernible or low CD63 levels in
NSCLC patients of various stages (Fig. S6‡). Thus, the exo-
somes collected from a cell line (ovarian cancer C30) were
included as a positive control for CD63 detection. Collec-
tively, these standard studies verify the microfluidic analysis
of the surface phenotypes of circulating exosomes. Both
microfluidic and standard methods detected significant
elevation of exosome abundance and exosomal markers in
NSCLC and OVCA, suggesting the potential clinical value of
circulating exosomes for cancer research and diagnostics.
Our microfluidic technology provides not only a general
approach for one-step isolation of exosomes directly from
plasma but also the ability to purify molecularly defined
subpopulations that are inaccessible to other physical
methods such as ultracentrifugation,41 nanofiltration26 and
size exclusion.13 Such capability would be beneficial for
deconvoluting the complexity of extracellular vesicles to
facilitate molecular classification and characterization of exo-
somes. The unique one-step isolation system also contrasts
with the conventional bulk immunomagnetic methods in
that it eliminates multiple, lengthy preparation steps of
washing and manual buffer exchange which can cause
damage and loss of exosomes.20,41,44This journal is © The Royal Society of Chemistry 2014
Fig. 4 Integrated microfluidic exosome analysis. (A) Schematic of
transmembrane IGF-1R in exosomes. We targeted the extravesicular
IGF-1R α unit and phosphorylated β domain inside the vesicle for
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View Article OnlineTo determine if the plasma-derived exosomes in NSCLC
show similar protein profiles to the tumor origin, we conducted
a three-color immunofluorescence histological (IFH) study of
patient-matched lung tumor tissues. High expression of
EpCAM, α-IGF-1R, CD9 and CD81 and low expression of CD63
were detected in the tumor tissues (Fig. 3D and S7‡), in agree-
ment with the subpopulation profiles of plasma exosomes
obtained by the microfluidic technology and the standard
analyses (Fig. 3 and S6‡). The matched molecular profiles
between circulating exosomes and tumor tissues support the
potential use of exosomes for non-invasive molecular profiling
of solid tumor tissue. Our studies also provide experimental
evidence to support recently arising questions on the use of
CD63 as a general surface marker for exosome isolation.43
Decreased CD63 expression has been found in relation to
tumour growth and invasiveness in lung and other cancers.45,46surface phenotyping and intravesicular protein analysis of exosomes.
(B) Chemical lysis of exosomes by using Triton X-100 as a surfactant as
observed by TEM. The scale bar is 100 nm. (C) Bright-field images of
the injection (top) and mixing (bottom) of the protein capture beads in
the serpentine channel. The scale bar is 200 μm. (D) The plot of the
minimum flow distance required for uniform mixing as a function
of flow rate ranging from 0.5 to 6 μL min−1. Inset: fluorescence
images taken at various distances along the channel after mixing a
stream of 0.1 μM of FITC-BSA solution with the bead suspension
co-flowing at the same flow rate. (E) The effect of incubation time
on chemifluorescence detection using alkaline phosphatase and the
substrate DiFMU. (F) Calibration of on-chip capture and detection of
IGF-1R and p-IGF-1R.Integrated exosome analysis for non-invasive detection of
cancer biomarkers
Recent profiling results of microRNAs contained inside
circulating exosomes have demonstrated the potential of
exosomes as surrogate markers for tumor biopsy.44,47 There
is increasing interest in proteomic characterization of
exosomes. Our ultimate goal is to develop a microfluidic
technology capable of measuring both surface and intra-
vesicular proteins of circulating exosomes. In this proof-of-
concept study, we demonstrated the integrated analysis of
two targets in NSCLC: total IGF-1R and phosphorylated
IGF-1R (p-IGF-1R). The IGF-1R pathway provides a potent pro-
liferative signaling system implicated in tumorigenesis and
metastasis. Phosphorylation of IGF-1R initiated by binding of
ligands, such as IGF-1, is required for activation of MAPK,
PI3K, AKT and other signaling pathways involved in cell pro-
liferation and survival.48 Thus there has been an intense
interest in the studies of IGF-1R and p-IGF-1R as diagnostic
markers and therapeutic targets.48–50 However, currently
immunohistochemical tests of tumor tissues predominate in
the clinical assessment of IGF-1R expression which are inva-
sive and problematic for regular monitoring of disease pro-
gression and response to treatment.51 To our best knowledge,
no studies of exosomal IGF-1R and p-IGF-1R have been
reported. As illustrated in Fig. 4A, IGF-1R is a transmembrane
protein composed of two surface α subunits and two intra-
vesicular β subunits containing a tyrosine kinase domain
which can be phosphorylated. Thus total IGF-1R and p-IGF-1R
provide good model targets for demonstrating microfluidic
surface phenotyping and intravesicular protein analysis of
exosomes. To avoid the interference from free proteins in
plasma, we used a monoclonal EpCAM antibody for exosome
capture and two antibodies that specifically recognize
α-IGF-1R and p-IGF-1R.
The unique cascading microfluidic immunocapture strat-
egy established here enables integration of exosome isolation
with downstream processing and analysis, i.e., chemical lysis,
flow mixing and protein capture, and chemifluorescence-basedThis journal is © The Royal Society of Chemistry 2014sandwich immunoassays. To chemically lyse the captured
exosomes, a mild non-ionic detergent, Triton X-100, was used
to lyse cells and yet retain the activity of proteins. The lysis
conditions, including Triton X-100 concentrations and incuba-
tion times, were studied and 5 min of incubation with 5%
Triton X-100 was found to be sufficient to completely lyse the
exosomes (Fig. 4B). The exosome lysate was flushed into a
serpentine microchannel to mix with magnetic beads conju-
gated with specific antibodies to capture the released protein
targets. To enhance fluidic mixing, the suspension of protein
capture beads was injected from two side channels to flank
the lysate stream (Fig. 4C, top), facilitating the mass transfer
across the channel.52 Uniform bead distribution across the
200 μm channel can be achieved within a travel distance of
~10 mm at 1 μL min−1 (Fig. 4C, bottom). Fluorescence
imaging was also employed to study the mixing behaviour,
revealing a linear response of the minimum distance for
complete mixing to flow rate in the range of 0.5 to 6 μL min−1
(Fig. 4D). This result provides guidance to optimize the chip
design and flow rate. In our system with a 25 cm mixing chan-
nel and a 4 mm microchamber, a flow rate of 1 μL min−1 was
used to yield a long incubation time of ~3.8 min which allows
efficient solid-phase affinity capture of proteins.53,54
We then optimized the on-chip bead-based immunoassay
and chemifluorescence readout using a matched pair of
capture/detection antibodies, an alkaline phosphatase
(AP)-conjugated secondary antibody, and the DiFMUPLab Chip, 2014, 14, 3773–3780 | 3777
Fig. 5 Quantitative detection of total IGF-1R in circulating exosomes
directly from clinical plasma samples. (A) The results of the integrated
microfluidic analysis presented in the bar (left) and scattered dot (right)
plots show significant overexpression of IGF-1R in EpCAM+ exosomes
of NSCLC patients compared to healthy controls (p = 0.0001,
CV = 11.2%). (B) Parallel ELISA analysis confirmed the overexpression of
IGF-1R in total exosomes purified from the same subjects by ultracen-
trifugation (p = 0.0097, CV = 56.4%). The error bars are standard
deviations (n = 3) in all cases.
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View Article Onlinesubstrate. The incubation time is an important factor for the
small-scale enzymatic chemifluorescence detection. It was
found that the fluorescence signal saturates after 6 min of
incubation in the microchamber (Fig. 4E), allowing for fast
on-chip protein detection. We then calibrated the on-chip
human IGF-1R and p-IGF-1R assays by running protein
standards through the entire process except the lysis step.
As plotted in Fig. 4F, the microfluidic assay achieved quanti-
tative detection of IGF-1R and p-IGF-1R over a dynamic range
of 4 logs with a detection limit of 0.281 pg mL−1 and
0.383 pg mL−1, respectively (S/N = 3). Such sensitivity is at
least 100-fold higher than that achieved by the commercial
ELISA kits (Fig. S9‡),55 which indicates efficient immuno-
precipitation of exosomal proteins in our microfluidic system.
With all the individual functions optimized, we finally
implemented the integrated microfluidic analysis to examine
the membrane protein IGF-1R and intravesicular p-IGF-1R
directly in the plasma of early-stage NSCLC patients (stage II).
The microfluidic results were compared to parallel ELISA
analysis of ultracentrifugation-purified vesicles from the same
patients (2 mL of plasma). To avoid interference from plasma
IGF-1R, we used an EpCAM antibody to capture tumor-
derived exosome subpopulations in 30 μL of patient plasma.
A potential problem may arise from the cross-reactivity of the
antibodies with insulin receptors (IRs) which share 80%
homology with IGF-1R.56 To investigate this effect, we tested
IGF-1R and p-IGF-1R antibodies from a number of vendors
using a commercial IR ELISA kit (Table S1‡). No cross-
reaction with IRs was detected for all the IGF-1R antibodies
(Fig. S8‡). Fig. 5A shows that the NSCLC patients overexpress
circulating exosomes with an EpCAM+/IGF-1R+ phenotype
and can be well discriminated from the control group
(p < 0.0001). The detected IGF-1R concentration was found to
correlate linearly with the total abundance of plasma vesicles
determined by NTA, while our method measured a fraction of
the circulating vesicles (Fig. S10‡). In addition, the quantita-
tive detection was achieved for vesicle concentrations much
lower than the healthy levels. These results validate the
method for sensitive and quantitative characterization of cir-
culating exosomes in clinical samples. IGF-1R overexpression
was also evident in the ELISA results presented in Fig. 5B
(p < 0.01), consistent with the previous observations reported
for NSCLC cell lines and tumor tissues.57–59 It is important to
note that ELISA detects the total IGF-1R level in all vesicle
types co-purified by ultracentrifugation, while our method
enables characterization of molecularly defined subpopulations.
The ability to probe the intravesicular contents of selected
subpopulations is critical for the comprehensive characteriza-
tion of exosomes and elucidation of their biological and
pathological implications. To this end, we measured the
intravesicular level of phosphorylated IGF-1R using the same
samples as above. Although considerable cross-talking was
observed between p-IGF-1R antibodies and IRs (Fig. S8‡), our
method is able to specifically detect p-IGF-1R without IR
interference because exosomal p-IGF-1R is captured by the
monoclonal anti-IGF-1R beads while other exosomal species3778 | Lab Chip, 2014, 14, 3773–3780are removed by washing. As seen in Fig. S11A,‡ the p-IGF-1R
profile showed no correlation with that of IGF-1R and the dis-
ease state, which was further confirmed by the ELISA analysis
(Fig. S11B‡). This result confirms the specificity of the anti-
bodies for detection of p-IGF-1R without discernible cross-
reaction with IGF-1R. Previous studies have also reported the
lack of correlation between p-IGF-1R and total IGF-1R levels
in NSCLC.33,49,57,60 Understanding this phenomenon would
require mechanistic studies of the IGF-1R signaling path-
ways, which are beyond the scope of this work. Overall, we
have demonstrated microfluidic isolation and targeted
proteomic analysis of exosomes directly from clinical plasma
samples, all integrated in one rapid workflow with high sen-
sitivity and specificity. Since many specific antibodies for
cancer biomarkers are commercially available, our method
can be readily extended to multiplexed proteomic analysis
of circulating exosomes in various cancer types. The plasma
volume required here was only ~1/100 of that for the conven-
tional protocols, indicating highly efficient exosome immuno-
capture and sensitive protein analysis of our method. This
advantage immediately addresses the challenges in exosome
purification, a key setback in the clinical development of
exosomal biomarkers.36,61
Conclusions
We have developed a microfluidic exosome analysis platform
that integrates immunoaffinity isolation and protein analysis
of tumor exosomes directly from human plasma. Relevant toThis journal is © The Royal Society of Chemistry 2014
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View Article Onlinefuture biomedical applications, we demonstrated profiling of
surface phenotypes associated with cancer and quantitative
analysis of surface and intravesicular biomarkers in a selected
exosome subpopulation directly from minimally invasive
plasma samples. Compared to the conventional methods,
our technology remarkably increases the sensitivity while
reducing the assay time and sample requirement. Owing to
its simplicity and general applicability, the exosome analysis
microchip can be readily scaled up for high-throughput
screening of cancer as well as non-cancerous diseases. There-
fore, we envision that this methodology holds the potential
to facilitate the elucidation of biological functions and
clinical implications of circulating exosomes.Acknowledgements
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